ATE207891T1 - Biphenylsulfonamid matrix metalloproteinase inhibitoren - Google Patents

Biphenylsulfonamid matrix metalloproteinase inhibitoren

Info

Publication number
ATE207891T1
ATE207891T1 AT97918788T AT97918788T ATE207891T1 AT E207891 T1 ATE207891 T1 AT E207891T1 AT 97918788 T AT97918788 T AT 97918788T AT 97918788 T AT97918788 T AT 97918788T AT E207891 T1 ATE207891 T1 AT E207891T1
Authority
AT
Austria
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
alkyl
biphenylsulfonamide
biphenylsulfonamide matrix
Prior art date
Application number
AT97918788T
Other languages
English (en)
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE207891T1 publication Critical patent/ATE207891T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AT97918788T 1996-05-17 1997-04-24 Biphenylsulfonamid matrix metalloproteinase inhibitoren ATE207891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
PCT/US1997/006801 WO1997044315A1 (en) 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE207891T1 true ATE207891T1 (de) 2001-11-15

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97918788T ATE207891T1 (de) 1996-05-17 1997-04-24 Biphenylsulfonamid matrix metalloproteinase inhibitoren

Country Status (23)

Country Link
EP (1) EP0901466B1 (de)
JP (1) JP2000511175A (de)
KR (1) KR20000011095A (de)
CN (1) CN1077885C (de)
AT (1) ATE207891T1 (de)
BG (1) BG63940B1 (de)
BR (1) BR9710841A (de)
CA (1) CA2253342A1 (de)
CZ (1) CZ294063B6 (de)
DE (1) DE69707865T2 (de)
DK (1) DK0901466T3 (de)
EA (1) EA001561B1 (de)
EE (1) EE03965B1 (de)
ES (1) ES2167733T3 (de)
HK (1) HK1019585A1 (de)
IL (1) IL126832A0 (de)
NO (1) NO312510B1 (de)
NZ (1) NZ332711A (de)
PL (1) PL186416B1 (de)
PT (1) PT901466E (de)
SK (1) SK282863B6 (de)
WO (1) WO1997044315A1 (de)
ZA (1) ZA974223B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ288298A (en) * 1994-06-22 1998-12-23 British Biotech Pharm Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
JP2001526631A (ja) * 1996-12-09 2001-12-18 ワーナー−ランバート・コンパニー 心不全および心拡張症の治療および予防方法
ES2212142T3 (es) * 1996-12-17 2004-07-16 Warner-Lambert Company Llc Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
EP1366765A1 (de) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc VerWendung von Matrix-Metalloproteinase Inhibitoren zur Behandlung von neurologischen Erkrankungen und zur Förderung der Wundheilung
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
ID29293A (id) * 1997-07-22 1999-01-28 Shionogi & Co KOMPOSISI UNTUK MENGOBATI ATAU MENCEGAH GLOMERULOPATI (Pecahan dari No. W20000054)
IL135428A0 (en) * 1997-12-23 2001-05-20 Warner Lambert Co Ace inhibitor-mmp inhibitor combinations
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
HUP0101176A3 (en) * 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
BR9815745A (pt) * 1998-03-17 2000-11-14 Warner Lambert Co Combinações de inibidor de metaloproteinase de matriz estatina
EP0967201A1 (de) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Sulphonamide enthaltende Arzneimittel als Matrix Metalloproteinase Inhibitoren
WO2000004030A1 (de) 1998-07-16 2000-01-27 Aventis Pharma Deutschland Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
KR20010083134A (ko) * 1998-07-21 2001-08-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
DK1249233T3 (da) 1999-11-26 2008-11-17 Shionogi & Co NPYY5-antagonister
AU2001292285A1 (en) * 2000-09-29 2002-04-15 Shionogi And Co., Ltd. Thiazole or oxazole derivatives
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) * 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
BR0318625A (pt) 2003-12-04 2006-10-31 Wyeth Corp biaril sulfonamidas e métodos para usar as mesmas
CN101001834B (zh) 2004-03-22 2011-06-29 南方研究院 基质金属蛋白酶的非肽抑制剂
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
NZ288298A (en) * 1994-06-22 1998-12-23 British Biotech Pharm Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors

Also Published As

Publication number Publication date
PL186416B1 (pl) 2004-01-30
EA199800988A1 (ru) 1999-04-29
CZ366898A3 (cs) 1999-02-17
SK282863B6 (sk) 2002-12-03
KR20000011095A (ko) 2000-02-25
EE03965B1 (et) 2003-02-17
CN1077885C (zh) 2002-01-16
BG102918A (en) 1999-09-30
EP0901466B1 (de) 2001-10-31
NO985326D0 (no) 1998-11-16
DK0901466T3 (da) 2002-02-18
EP0901466A1 (de) 1999-03-17
EA001561B1 (ru) 2001-04-23
EE9800397A (et) 1999-06-15
BR9710841A (pt) 1999-08-17
CA2253342A1 (en) 1997-11-27
SK157798A3 (en) 1999-04-13
CN1219166A (zh) 1999-06-09
NO985326L (no) 1999-01-14
NZ332711A (en) 2000-06-23
IL126832A0 (en) 1999-08-17
ES2167733T3 (es) 2002-05-16
BG63940B1 (bg) 2003-07-31
NO312510B1 (no) 2002-05-21
AU713286B2 (en) 1999-11-25
DE69707865D1 (de) 2001-12-06
DE69707865T2 (de) 2002-05-02
CZ294063B6 (cs) 2004-09-15
ZA974223B (en) 1997-12-10
JP2000511175A (ja) 2000-08-29
HK1019585A1 (en) 2000-02-18
PL329929A1 (en) 1999-04-26
AU2680397A (en) 1997-12-09
WO1997044315A1 (en) 1997-11-27
PT901466E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
DK0901466T3 (da) Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer
AU6894800A (en) Caspase inhibitors and uses thereof
GB9801690D0 (en) Therapeutic agents
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
WO2003024448A3 (en) Inhibitors of histone deacetylase
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE69736945D1 (de) Biphenylverbindungen sowie ihre anwendung als östrogene mittel
PL317349A1 (en) Organic compounds
DE69731642D1 (de) Buttersäure matrix-metalloproteinase-inhibitoren
BR0214886A (pt) Fenilalquinos
AU5230898A (en) Metalloproteinase inhibitors
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee